Skip to main content
. 2022 Nov 22;13:7171. doi: 10.1038/s41467-022-34917-y

Fig. 3. rs28714259 risk allele or loss of rs28714259 locus decreases dexamethasone -induced protection of viability and contractility after doxorubicin exposure.

Fig. 3

Cells were pretreated with or without dexamethasone before exposed to doxorubicin. Viability (a), normalized peak height (contractile strength) (b), and normalized beat rate (c) were evaluated in intrinsically polymorphic hiPSC-derived cardiomyocyte cell (hiPSC-CM) lines. Viability (d), normalized peak height (e), and normalized beat rate (f) were also assessed in rs28714259 deleted hiPSC-CM lines. g Representative curves of contraction amplitude in two rs28714259 intrinsically polymorphic hiPSC-CM lines of GG (left) and AA (right) genotypes, respectively. Contractility was analyzed using Cellogy Pulse from recorded movies of beating cardiomyocytes. rs28714259 intrinsically polymorphic lines are labeled as GG, GA, and AA; rs28714259 deletion lines are labeled as +/+, +/−, and −/−. Three lines/genotype for the intrinsically polymorphic hiPSC-CMs (GG/GA/AA) and two lines/genotype for genome-modified hiPSC-CMs [(+/+)/(+/−)/(−/−)] were measured with four technical replicates for each line. Results for each treatment in the intrinsic (n = 12) and genome-modified (n = 8) lines are plotted (dots). Data are represented as mean ± sd. Two-way ANOVA followed by Tukey’s multiple comparisons test was used to estimate significance. P-values are indicated in the figure. Con control, DOX doxorubicin, DEX dexamethasone. Source data for Fig. 3a–f are provided as a Source Data file.